Skip to content
Home » Experts Are Worried About Tuberculosis Again

Experts Are Worried About Tuberculosis Again

Sign up to The WeekDay newsletter

A free twice-daily digest of the biggest news stories of the day – and the best features from our website

Thank you for signing up to TheWeek. You will receive a verification email shortly.

There was a problem. Please refresh the page and try again.

Tuberculosis, commonly abbreviated as TB, may be on its way to becoming a global crisis, according to the United Nations. The deadly disease once again claimed its spot as the number one infectious killer globally in October of 2022, overtaking Covid-19, AFP reported. While progress was being made against the disease, the arrival of Covid in 2020 was a setback that caused cases to swell for the first time in a decade. “​We went from what I honestly consider to be unbelievably slow progress, but at least progress, to a reversal,” Mel Spigelman, president of the non-profit TB Alliance, told AFP in 2022. 

TB is a highly contagious disease that“knows no borders,” Dr. Lucica Ditiu, executive director of the U.N.-hosted organization Stop TB Partnership, told Time. “So long as you breathe, you can still catch TB.” While antibiotics were developed to fight the disease, new strains of drug-resistant TB have evolved, causing higher rates of mortality. Approximately 3.6% of today’s new tuberculosis cases are resistant to multiple TB drugs. “There’s no biological reason that multi-drug-resistant TB can’t acquire what it takes to transmit easily,” David Bishai, the director of the school of public health at the University of Hong Kong, told Time. “And so this does represent a pandemic threat.”

To fight the new strains, pharmaceutical company Johnson & Johnson developed a drug called bedaquiline that is effective against drug-resistant TB. The company also opted to not enforce secondary patents on the drug, allowing “current and future generic manufacturers” the ability to “manufacture and sell high-quality generic versions,” as long as the generic versions are “of good quality, medically acceptable,” and are only used in 134 specific low and middle-income countries, according to a J&J press release. 

Subscribe to The Week The Week provides readers with a wide range of perspectives from 200 trusted news sources.

Try 6 Free Issues

Sign up for The Week’s Free Newsletters From our daily WeekDay news briefing to an award-winning Food & Drink email, get the best of The Week delivered directly to your inbox.

From our daily WeekDay news briefing to an award-winning Food & Drink email, get the best of The Week delivered directly to your inbox.

Continue reading for free

We hope you’re enjoying The Week’s refreshingly open-minded journalism.

Subscribed to The Week? Register your account with the same email as your subscription.